Thank you, operator. Good morning, everyone, and a warm welcome to Egetis Therapeutics' Q3 results call, planned for the next 30 minutes. For those who haven't had the privilege to meet me before, I'm Nicklas Westerholm, the CEO of the company. With me today, I also have Yilmaz Mahshid, Chief Financial Officer; Henrik Krook, Vice President, Commercial Operations; Karl Hård, Vice President, Investor Relations; and Christian Sonesson, Vice President, Product Strategy and Development. So let's turn our attention to the topics that will be covered today.
I am very pleased with the great progress made during the quarter and after the period, among other achievements. The FDA awarded us a Breakthrough Therapy Designation for Tiratricol on the 14th of July this year. We had a very successful pre-NDA meeting on October 21st with the FDA, with the agreement that Egetis can submit the NDA for Emcitate based on currently available data. Subsequently, we completed the ReTRIACt study of Emcitate and announced positive results, which leads to us being able to commence a rolling NDA submission in December this year.
Furthermore, we will also cover the commercialization in Europe and launch preparations in the US, as well as provide a financial update, leaving ample time for questions. Let's begin with the Breakthrough Therapy Designation granted by the FDA on July 14th.
In the first quarter of 2025, we received the entire data set from the Erasmus Medical Center, also called EMC, in Rotterdam, containing survival data from more than 600 patients with MCT8 deficiency. Approximately one-third of the patients had been treated with tiratricol, while two-thirds had not. We submitted a Breakthrough Therapy Designation application based on our own detailed analysis of the survival data, which confirmed a significant and substantial improvement in survival in tiratricol-treated patients.
The breakthrough designation underscores both the urgent need for an effective treatment for patients with MCT8 deficiency and the clinically meaningful evidence demonstrated today. Tiratricol receiving a breakthrough designation this late in the clinical development program is, of course, very encouraging for the forthcoming NDA process, as these designations are typically awarded at an early stage in development. Let's now focus on the outcome of the Pre-NDA meeting with the FDA.
The objective of today's meeting was to seek FDA advice and agreement on the overall content to support our New Drug Application for Emcitate in the US, with a special focus on the clinical data package, including the role and position of the ReTRIACt study. Importantly, and as agreed with the FDA, the NDA for Emcitate will be based on currently available clinical data.
Furthermore, the ReTRIACt study is no longer considered pivotal for the NDA, unlike when the study was initially designed. FDA agreed that in the NDA submission, data from the ReTRIACt study will complement the existing data package from the EMC Survival Study and other clinical components.
The FDA also recommended that the statistical analysis plan be revised. The SAP for the trial should be revised, recognizing that MCT8 deficiency is an ultra-rare condition. We have an unusually large and robust clinical data set from six different sources. This includes Triac Trial One with 46 patients. Triac Trial two involved 22 patients. The ReTRIACt study with 15 patients. The EMC cohort study includes 67 patients, and the EMC Survival Study involves over 600 patients.
Furthermore, we also reached an agreement with the FDA that we can commence a rolling NDA submission in December 2025, targeting a complete NDA submission in early 2026, and anticipating completion of the FDA review process in the third quarter of 2026. We expect a priority review. So, in summary, as I'm sure you all appreciate, we are very pleased with the outcome of the meeting and the clear path to an NDA submission for Emcitate in the US, based on currently available clinical data.
Let's now turn our attention to the positive outcome of the ReTRIACt study.
On the 14th of November, we issued a press release announcing positive topline results from the ReTRIACt study with Emcitate, based on the comments from the FDA at the NDA meeting. The statistical analysis plan of the ReTRIACt study was revised with the intention to conclude the study prematurely. The revised SAP focuses on more efficient use of the data collected during the randomized treatment period, or RTP, using all T3 data, not only the binary information on rescue yes or no. That's why we consider the rate of change in T3 during the RTP, using all patient data on T3 collected to increase the statistical power of the study.
Subsequently, a primary endpoint evaluating the rate of change in T3 during the RTP was added to the previously described primary endpoint based on T3 rescue criteria. From here on, referred to as primary endpoint two, Type I error is controlled via alpha recycling, testing primary endpoint one first, and if primary endpoint one is met, primary endpoint two will then be tested. The revised statistical plan was submitted to the FDA before database lock and unblinding of the ReTRIACt study, and as announced, the positive top-line results demonstrate a statistically significant difference in the rate of change in T3 in patients randomized to placebo versus patients continuing on tiratricol with a p-value of 0.034.
And if you furthermore look at the results depicted here on the slide, what you see depicted to the left is the ranking of patients according to their change in T3 during the 30-day randomized treatment period.
Displayed with a dashed line is the line of no change from the baseline.
Hence, the patients with the largest increase in T3 during the RTP are at the top of the figure, and the patients with the largest decrease are at the bottom of the figure. What we observed regarding T3 movements is exactly what we expected; when withdrawing Tiratricol, the T3 levels in all placebo patients increase, but not much changes across the entire group. In fact, there is a complete separation between the two groups, with all patients randomized to placebo experiencing a larger increase in T3 compared to all seven patients randomized to Tiratricol. So what does this really tell us? And what does this mean for the results on the primary endpoint?
On the right-hand side, the upper table shows the results for primary endpoint one.
The rate of change in T3 during the RTP. For the placebo group, the T3 rate of change was 1.59, which means a 59 percent increase in T3 over 30 days. Whereas there was essentially no change for the tiratricol group, there was a statistically significant difference between placebo and tiratricol, expressed here as the ratio of the T3 rate of change, which was 1.494, with a p-value equal to 0.034. In the lower table, you can see the results for primary endpoint two: patients randomized to placebo met the rescue criterion, and no patients randomized to tiratricol met the rescue criterion. One patient randomized to tiratricol discontinued during the RTP. This discontinuation was not drug-related, and the patient is marked with a D in the left-hand figure. As you can see, there was no change in T3 during the RTP. However, as per the SAP, this patient was still imputed as a rescue for the analysis of primary endpoint two, leading to a four placebo versus one tiratricol comparison for primary endpoint two, which is not statistically significant. However, the sensitivity analysis below only considered the observed cases of rescue, leading to a comparison of four patients meeting the rescue criteria on placebo versus zero patients randomized to Tiratricol with a p-value of 0.070. Although not shown on this slide, after the RTP was completed, patients randomized to placebo reinitiated tiratricol treatment, and they all showed an expected decrease in T3 levels in the follow-up period. So to conclude, we are very pleased with the outcome from the pre-NDA meeting with the FDA and subsequently the positive ReTRIACt study outcome. As previously communicated, we now plan to submit an NDA for Emcitate with the currently available clinical data.
We have a very robust data set for such a rare disorder, including data from the trials previously mentioned, and this could be visible here on the slide. Our plan is to commence a rolling submission in December 2025, targeting a complete NDA submission in early 2026, with an update and an anticipated completion of the FDA review process in the third quarter of 2026. With that, I will hand over to Henrik for an update on commercialization in Europe and the launch preparations in the US.
Thank you, Nicklas, and good morning, everyone. I would like to start by giving a reminder and an update on our commercialization strategy. So we plan to commercialize Emcitate (tiratricol) through our team in Europe and the US. For other regions, we intend to collaborate with partner companies to ensure broad access to Emcitate® for patients. We have started executing this strategy by initiating the commercialization of Emcitate in Europe and beginning market preparations in the United States for the rest of the world. We have a license deal with Fujimoto for the development and commercialization in Japan. In June, we announced our first distribution deal, an agreement with Er-Kim for Turkey. I'm very pleased with how this collaboration is working. The Er-Kim team is in dialogue with several physicians and payers regarding the funding of Emcitate for identified patients. In October, we announced our second distribution deal, an agreement with Taiba to enable Emcitate access and named patient sales in the Gulf region.
Initially Saudi Arabia, United Arab Emirates, Qatar, Oman, and Bahrain, and the ambition is to extend to more countries over time.
So all in all, we continue to deliver on our commercialization strategy with our focus on reaching patients with urgent unmet medical needs. As we continue to execute our European commercialization strategy, I'm pleased to report steady progress across key markets with pricing and reimbursement processes moving forward in parallel. In Germany, we have successfully transitioned all managed access patients to the commercial Emcitate product. Our ongoing dialogues with physicians are delivering greater awareness of MCT8 deficiency, resulting in new patient identifications and treatment initiations. In France, our first reimbursement submission was rejected in September by the French Health Authority. This is not uncommon when it comes to orphan drugs in France, since the authority ideally would like to see randomized controlled data.
We are now preparing a resubmission in early 2026 to address the payer objections, and will then include newly available data, such as the recently announced positive, placebo-controlled data from the ReTRIACt study. In this process, in addition to new data, we also have strong support from physicians who already have patients on Emcitate treatment. In Italy, the pricing and reimbursement process is underway, and commercial product is now available to patients. The pricing and reimbursement process is underway, and the commercial product is now available to patients in Spain. We recently held a successful advisory board with physicians and have secured support to generate local data to optimize our upcoming pricing and reimbursement submission. Beyond our core European markets, we are actively utilizing alternative funding pathways to facilitate named patient sales in additional countries.
To date, this approach has enabled us to successfully provide Emcitate to patients in Poland, Austria, and Switzerland. Overall, we are delivering tangible results by expanding patient access and building momentum for Emcitate across Europe. Let me also walk through our US pre-launch progress, where we continue to execute with strong discipline. We have made significant strides in expanding our reach among healthcare providers and accelerating the diagnostic pathway for MCT8 deficiency. We have increased our engagements in endocrinology, genetics, and neurology with enhanced diagnostic considerations for MCT8 deficiency. Our partnerships with key opinion leaders and patient advocacy groups remain vital in raising awareness and supporting families. This momentum is translating into real impact, validating our awareness efforts.
We are now aware of approximately 140 diagnosed patients in the US. Our Expanded Access Program is active at 15 sites, providing early access for eligible patients, generating valuable clinical insights, and building operational experience ahead of launch. On market access, we have advanced our readiness by engaging with payers and stakeholders, directly informing our launch pricing strategy, and strengthening our overall framework for distribution and patient services.
Finally, we have recently added employees to our US organization, establishing core leadership and expanding our field medical capabilities to ensure the clinical community is prepared to diagnose and treat patients once Tiratricol is approved by the FDA.
So in summary, we are executing our pre-launch strategy across four pillars: medical awareness and diagnostic acceleration, early access, market access readiness, and scalable launch infrastructure.
With these foundations, we are confident in our ability to deliver a strong commercial launch and bring a transformative therapy to children and families living with MCT8 deficiency once regulatory approval is secured.
With that, I would like to hand over to Yilmaz Mahshid for the financial update.